Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed ...

Indoco Remedies receives US FDA final approval for its ANDA for lacosamide oral solution USP, 10 mg/mL: Our Bureau, Mumbai Friday, January 30, 2026, 14:30 Hrs [IST] Indoco Remedie ...

In other developments, a federal court rejected, for now, the EPA’s move to rescind drinking-water limits for 4 PFAS ...

Lacosamide Oral Solution is used in the treatment of partial onset seizures and primary generalised tonic-clonic seizures in adults and children aged four years and above with epilepsy.

EXCLUSIVE — The Environmental Protection Agency has begun a multiyear study to determine the maximum safe level of fluoride in the nation’s drinking water, advancing a key objective of the “Make ...

Indoco Remedies receives USFDA approval to market generic Lacosamide oral solution for epilepsy treatment. Manufactured in Goa facility.

Kymera Therapeutics KYMR announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to ...

Altria Group (NYSE:MO) executives highlighted “continued momentum” in 2025, pointing to adjusted earnings growth, cash ...

The health benefits of dietary flavanols appear to come from their ability to trigger responses in the brain and the body’s stress systems. That slightly dry, tightening feeling some foods leave in ...

A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...

Optimized treatment of lichen planopilaris should be individualized in the context of presenting symptoms and features, according to a newly tweaked algorithm.

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...